Examining CV Effects of Basal Insulin Therapy

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Type 2 Diabetes (T2D) Major Medical and Societal Challenge

Glycemic Control ~100 Million People in the United States

Basal Insulin Development

Basal Insulin Titration in the Treat-to-Target Trial Glargine vs NPH

Novel Basal Insulin Glargine U-300

More Sustained Reductions in HbA1c With Glargine U-300

Participants on Glargine U-300 Had Less Nocturnal Hypoglycemia and Any Time of Day Hypoglycemia

Greater Daily Basal Insulin Dose With Glargine U-300 and Less Weight Gain

Novel Basal Insulin Degludec

Insulin Glargine vs Insulin Degludec Variability

Outcome Reduction With an Initial Glargine Intervention ORIGIN Trial

Participants in ORIGIN Key Inclusion Criteria

Interventions (Added to Lifestyle)

Median Glargine Dose & IQR (U/kg)

Median HbA1c Levels

Hypoglycemia and Weight (6 to 7 years)

1st Co-Primary Endpoint MI, Stroke, or CV Death

2nd Co-Primary Endpoint: MI, Stroke, or CV Death, Revascularization, Heart Failure

DEVOTE CVOT with Insulin Degludec Trial Design

Time to First 3-Point MACE

Basal Insulin Dose (U/kg)

Glycemic Control

Rates of Severe Hypoglycemia

Rates of Nocturnal Severe Hypoglycemia

DEVOTE Confirmed the Results From BEGIN and SWITCH With Regards to Hypoglycemia in Patients With T2D

Fear of Hypoglycemia Conflicts with Treatment Success for Both Patients and Clinicians

Systematic Review: Association of Hypoglycemia With Outcomes

Interpreting the Data and Clinical Implications Can We Compare ORIGIN vs DEVOTE?

DELIVER 2: Hypoglycemia-Related Data

Concluding Remarks

Concluding Remarks (cont)

Abbreviations

Abbreviations (cont)